Last checked at 4 Feb 2016 07:00
4 February 2016
IXICO plc Director's dealings
4 February 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that it was notified on 3 February 2016 that, on the same day, Dr Andrew Richards, Non-Executive Chairman of the Company, purchased 45,899 Ordinary Shares of 1p each in IXICO at a price of 32.68p pence per Ordinary Share through his self-invested pension plan ("SIPP"), of which he is the sole beneficiary. As a consequence of this share purchase, Dr Andrew Richards is beneficially interested in 76,099 Ordinary Shares representing 0.29% of the Company's issued share capital.
Enquiries:
IXICO plc | +44 20 3763 7499 |
Derek Hill, CEO | |
Susan Lowther, CFO | |
Peel Hunt LLP (Nominated Adviser and Broker) | +44 20 7418 8900 |
James Steel / Oliver Jackson | |
Daniel Stewart & Company (Joint Broker) | +44 207 776 6550 |
Martin Lampshire / David Coffman | |
FTI Consulting Limited (Investor Relations) | +44 20 3727 1000 |
Simon Conway / Mo Noonan / Matthew Moss |
Notes to Editors
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.